This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Karim, M Y Articles by Hunt, B J Search for Related Content PubMed PubMed Citation Articles by Karim, M Y Articles by Hunt, B J Social Bookmarking                         What's this?

Hypertension as the presenting feature of the antiphospholipid syndrome

Lupus Research Unit, The Rayne Institute, London; Department of Immunology, St Thomas' Hospital, London, UK; yousuf.karim{at}gstt.sthames.nhs.uk

P Alba

Lupus Research Unit, The Rayne Institute, London

M F Tungekar

Department of Histopathology, St Thomas' Hospital, London, UK

I C Abbs

Lupus Research Unit, The Rayne Institute, London; Department of Nephrology, Guy's and St Thomas' Hospitals, London, UK

M A Khamashta

Grv Hughes

B J Hunt

Lupus Research Unit, The Rayne Institute, London

The antiphospholipid or Hughes syndrome is the association between antiphospholipid antibodies (aPL), venous and arterial thromboses and pregnancy morbidity.¹ Antiphospholipid syndrome (APS) commonly coexists with autoimmune diseases usually systemic lupus erythematosus (SLE), when it is known as secondary APS. When present in isolation it is known as primary APS (PAPS). Although the kidney may be affected in APS, its involvement is perhaps not as well described as that of other organs. Thrombotic microangiopathy (TMA) affecting the kidney has been reported as a manifestation in both primary and secondary APS. This report describes hypertension related to underlying renal TMA as a presenting symptom of APS.

Key Words: antiphospholipid syndrome • hypertension • thrombotic microangiopathy

Lupus, Vol. 11, No. 4, 253-256 (2002)
DOI: 10.1191/0961203302lu179cr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S Masood, D Jayne, and Y Karim Beyond immunosuppression - challenges in the clinical management of lupus nephritis Lupus, February 1, 2009; 18(2): 106 - 115. [Abstract] [PDF]

				J Sastre-Garriga and X Montalban APS and the brain Lupus, December 1, 2003; 12(12): 877 - 882. [Abstract] [PDF]

				C Korkmaz, S Kabukcuoglu, S Isiksoy, and A U Yalcin Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy Lupus, October 1, 2003; 12(10): 760 - 765. [Abstract] [PDF]

				C P Mavragani and H M Moutsopoulos Lupus nephritis: current issues Ann Rheum Dis, September 1, 2003; 62(9): 795 - 798. [Full Text] [PDF]

				P Alba, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M A Khamashta, D D'Cruz, and G R V Hughes Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis Ann Rheum Dis, June 1, 2003; 62(6): 556 - 560. [Abstract] [Full Text] [PDF]